Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THR004
MIFTS: 51

Thrombocytosis

Categories: Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thrombocytosis

About this section

MalaCards integrated aliases for Thrombocytosis:

Name: Thrombocytosis 12 74 29 54 43 15 71
Thrombocythaemia 12

Classifications:

MalaCards categories:
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2228
MeSH 43 D013922
NCIt 49 C35530
SNOMED-CT 67 6631009 79574003
UMLS 71 C0836924
Sources

Summaries for Thrombocytosis

About this section
Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to transient erythroblastopenia of childhood and splenomegaly. An important gene associated with Thrombocytosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Thrombocythemia, also called thrombocytosis and thrombophilia, is the presence of a high platelet... more...

Sources

Related Diseases for Thrombocytosis

About this section

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 731)
# Related Disease Score Top Affiliating Genes
1 transient erythroblastopenia of childhood 32.5 KITLG EPO
2 splenomegaly 31.5 MPL JAK2 EPO
3 iron deficiency anemia 31.3 THPO IL6 EPO CRP
4 refractory anemia 31.3 TET2 MPL IL3 EPO CSF3
5 myelodysplastic/myeloproliferative neoplasm 31.2 TET2 JAK2 CSF2
6 polycythemia vera 31.0 THPO TET2 SELP MPL KITLG JAK2
7 paraneoplastic syndromes 31.0 IL6 CSF3
8 thrombophilia due to thrombin defect 30.9 SERPINC1 F3 F2
9 blood platelet disease 30.8 THPO SERPINC1 SELP MPL JAK2 IL6
10 essential thrombocythemia 30.8 THPO TET2 SERPINC1 SELP PPBP MPL
11 granulocytopenia 30.7 IL3 CSF3 CSF2
12 platelet aggregation, spontaneous 30.7 SERPINC1 SELP
13 osteomyelitis 30.7 IL6 IL1B CSF3
14 osteosclerotic myeloma 30.7 IL6 IL1B
15 myeloid leukemia 30.7 TET2 LIF JAK2 IL3 CSF3 CSF2
16 erythrocytosis, familial, 1 30.6 JAK2 IL3 EPO
17 acute leukemia 30.6 THPO JAK2 IL3 CSF3 CSF2
18 acute cystitis 30.6 IL6 F2 CRP
19 coronary thrombosis 30.6 SERPINC1 SELP F3
20 portal hypertension 30.5 THPO JAK2 F3 F2
21 lateral sinus thrombosis 30.5 SERPINC1 F2
22 thrombocytopenic purpura, autoimmune 30.5 THPO SELP MPL IL11
23 pulmonary embolism 30.5 SERPINC1 F3 F2 CRP
24 amegakaryocytic thrombocytopenia, congenital 30.5 THPO MPL JAK2 IL3
25 intracranial hypertension 30.5 SERPINC1 IL1B F3 F2
26 thrombocytopenia due to platelet alloimmunization 30.4 THPO SELP MPL
27 heparin-induced thrombocytopenia 30.4 SERPINC1 F3
28 budd-chiari syndrome 30.4 SERPINC1 MPL JAK2 F3 F2
29 bacterial meningitis 30.4 IL6 IL1B CSF2 CRP
30 thrombophilia due to activated protein c resistance 30.4 SERPINC1 F3 F2
31 angina pectoris 30.4 IL6 F3 CRP
32 sagittal sinus thrombosis 30.3 SERPINC1 F3 F2
33 poems syndrome 30.3 IL6 IL1B EPO CSF3
34 active peptic ulcer disease 30.3 F3 F2 CRP
35 polyarteritis nodosa 30.3 SELP IL6 CRP
36 iritis 30.3 IL6 EPO CRP
37 portal vein thrombosis 30.3 SERPINC1 SELP MPL JAK2 F2 CRP
38 spinal cord infarction 30.3 SERPINC1 F2
39 nonarteritic anterior ischemic optic neuropathy 30.3 SERPINC1 F2 CRP
40 acute monoblastic leukemia 30.3 IL6 EPO CSF2
41 polyneuropathy 30.3 IL6 IL1B EPO CRP
42 relapsing polychondritis 30.3 IL6 CSF3 CRP
43 systemic mastocytosis 30.3 TET2 KITLG JAK2
44 vitamin k deficiency bleeding 30.3 SERPINC1 F3 F2
45 peripheral nervous system disease 30.2 IL6 IL1B CSF3 CRP
46 eosinophilic gastroenteritis 30.2 IL3 CSF3 CSF2
47 meningitis 30.2 IL6 IL1B CSF3 CSF2 CRP
48 proteasome-associated autoinflammatory syndrome 1 30.2 SELP IL6 IL1B CRP
49 cavernous sinus thrombosis 30.2 SERPINC1 F2 CRP
50 cholesterol embolism 30.2 SERPINC1 F2 CRP

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis
Sources

Symptoms & Phenotypes for Thrombocytosis

About this section

MGI Mouse Phenotypes related to Thrombocytosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.34 CD177 CSF2 CSF3 EPO F2 F3
2 immune system MP:0005387 10.3 CD177 CRP CSF2 CSF3 EPO F2
3 cardiovascular system MP:0005385 10.29 CRP CSF2 EPO F2 F3 IL1B
4 homeostasis/metabolism MP:0005376 10.25 CRP CSF2 EPO F2 F3 IL1B
5 embryo MP:0005380 10.11 CSF2 EPO F2 F3 JAK2 KITLG
6 integument MP:0010771 10.06 CSF2 CSF3 EPO F2 F3 IL1B
7 mortality/aging MP:0010768 9.97 CSF2 EPO F2 F3 IL1B IL6
8 liver/biliary system MP:0005370 9.86 EPO IL6 JAK2 KITLG LIF SELP
9 neoplasm MP:0002006 9.5 CSF2 F3 IL1B IL6 JAK2 KITLG
10 respiratory system MP:0005388 9.23 CSF2 EPO F2 F3 IL6 JAK2
Sources

Drugs & Therapeutics for Thrombocytosis

About this section

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
4
Anagrelide Approved Phase 3 68475-42-3 2182
5
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
6
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
7
Hydroxyurea Approved Phase 3 127-07-1 3657
8
Mercaptopurine Approved Phase 3 50-44-2 667490
9
Melphalan Approved Phase 3 148-82-3 4053 460612
10
Danazol Approved Phase 3 17230-88-5 28417
11
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
12
Lactitol Investigational Phase 2, Phase 3 585-86-4, 585-88-6 493591
13 Anti-Inflammatory Agents Phase 3
14 Anti-Inflammatory Agents, Non-Steroidal Phase 3
15 Analgesics, Non-Narcotic Phase 3
16 Antipyretics Phase 3
17 Analgesics Phase 3
18 Cyclooxygenase Inhibitors Phase 3
19 Fibrinolytic Agents Phase 2, Phase 3
20 Platelet Aggregation Inhibitors Phase 2, Phase 3
21 Interferon-alpha Phase 2, Phase 3
22 Protein Kinase Inhibitors Phase 3
23 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
24 Hormones Phase 3
25 Immunologic Factors Phase 3
26 Anti-Infective Agents Phase 3
27 Antiviral Agents Phase 3
28 Mitogens Phase 3
29 Androgens Phase 3
30 Interferon alpha-2 Phase 3
31 Hormone Antagonists Phase 3
32 Estrogens Phase 3
33 Hepcidins Phase 3
34 Estrogen Receptor Antagonists Phase 3
35 Estrogen Antagonists Phase 3
36 interferons Phase 3
37 Janus Kinase Inhibitors Phase 3
38 glucocorticoids Phase 3
39
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
40
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
41
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
42
Pomalidomide Approved Phase 2 19171-19-8
43
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
44 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
45
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
46
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
47
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
48
Lenalidomide Approved Phase 2 191732-72-6 216326
49
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
50
leucovorin Approved Phase 2 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients. Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
3 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
4 An Open Label, Multi-center, Phase IV Rollover Protocol for Patients Who Have Completed a Global Novartis or Incyte Sponsored Ruxolitinib (INC424) or Ruxolitinib and Panobinostat (LBH589) Combination Study and Are Judged by the Investigator to Benefit From Continued Treatment Recruiting NCT02386800 Phase 4 Ruxolitinib;Panobinostat
5 A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment Recruiting NCT03232177 Phase 4 Anagre Cap.
6 A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
7 A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
8 A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
9 A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
10 A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
11 An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF). Completed NCT01493414 Phase 3 INC424
12 A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0) Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
13 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
14 A Phase 3b, Multicenter, Single-arm, Open-label Safety AND Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Recruiting NCT03755518 Phase 3 FEDRATINIB
15 A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib Recruiting NCT03952039 Phase 3 FEDRATINIB;Best Available Therapy (BAT)
16 French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
17 A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
18 A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study Active, not recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
19 A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
20 A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis Active, not recruiting NCT04173494 Phase 3 Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol
21 Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms. Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
22 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
23 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
24 A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia. Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
25 A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Unknown status NCT01298934 Phase 1, Phase 2 LBH589
26 A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
27 A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia. Completed NCT00413634 Phase 2 anagrelide hydrochloride
28 An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation Completed NCT00586651 Phase 2 lestaurtinib
29 A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
30 A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN) Completed NCT02125318 Phase 2 Anagrelide CR
31 A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy Completed NCT01243073 Phase 2 Imetelstat
32 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Completed NCT00745550 Phase 1, Phase 2 SB1518
33 Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Completed NCT02124746 Phase 2 Momelotinib
34 A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis Completed NCT01392443 Phase 2 Ruxolitinib
35 An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L Completed NCT01348490 Phase 2 Ruxolitinib (INCB018424)
36 A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET) Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
37 A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis Completed NCT00039416 Phase 2 imatinib mesylate
38 A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2 Simtuzumab;Ruxolitinib
39 A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. Completed NCT02966353 Phase 2 ruxolitinib
40 Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Completed NCT00949364 Phase 2 Pomalidomide
41 A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01692366 Phase 2 SAR302503
42 A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM) Completed NCT00047190 Phase 2 tipifarnib
43 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) Completed NCT00003239 Phase 2 Cytarabine;Omacetaxine Mepesuccinate
44 A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia Completed NCT00227591 Phase 2 lenalidomide;prednisone
45 A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases Completed NCT00606307 Phase 2 ITF2357
46 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
47 Phase I/II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT00052520 Phase 1, Phase 2
48 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
49 A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies Completed NCT01731951 Phase 2 Imetelstat
50 A Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability & Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01236638 Phase 2 Momelotinib

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Uracil Mustard

Cochrane evidence based reviews: thrombocytosis

Sources

Genetic Tests for Thrombocytosis

About this section

Genetic tests related to Thrombocytosis:

# Genetic test Affiliating Genes
1 Thrombocytosis 29
Sources

Anatomical Context for Thrombocytosis

About this section

MalaCards organs/tissues related to Thrombocytosis:

40
Myeloid, Bone, Bone Marrow, Lung, Liver, Heart, Testes
Sources

Publications for Thrombocytosis

About this section

Articles related to Thrombocytosis:

(show top 50) (show all 4975)
# Title Authors PMID Year
1
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. 54 61
20154217 2010
2
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. 54 61
20151976 2010
3
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. 54 61
20197548 2010
4
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. 54 61
19903679 2010
5
JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. 54 61
19643476 2010
6
Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. 54 61
20194236 2010
7
Class prediction models of thrombocytosis using genetic biomarkers. 54 61
19773543 2010
8
[Diabetes insipidus followed, after 4 years, with dysarthria and mild right-sided hemiparesis--the first clinical signs of Erdheim-Chester disease. Description and depiction of a case with a review of information on the disease]. 54 61
20070034 2009
9
[Paediatric myofibroblastic tumours. A presentation of three cases]. 54 61
19647502 2009
10
JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia. 54 61
19999391 2009
11
Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. 54 61
19657484 2009
12
Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. 54 61
19303685 2009
13
Granulocytosis and thrombocytosis in renal cell carcinoma: a pro-inflammatory cytokine response originating in the tumour. 54 61
19581670 2009
14
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia. 54 61
19252138 2009
15
A case of acute promyelocytic leukemia showing transient thrombocytosis caused by increased interleukin-6 and thrombopoietin after treatment with all-trans retinoic acid and chemotherapy. 54 61
19461187 2009
16
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia. 54 61
19222478 2009
17
[A case of IL-6 producing malignant mesothelioma of abdomen with thrombocytosis]. 54 61
19346724 2009
18
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. 54 61
18845793 2009
19
Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. 54 61
18796624 2009
20
Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. 54 61
19036112 2009
21
Mice overexpressing murine oncostatin M (OSM) exhibit changes in hematopoietic and other organs that are distinct from those of mice overexpressing human OSM or bovine OSM. 54 61
19112126 2009
22
Anagrelide: 20 years later. 54 61
19105705 2009
23
Thrombocytosis. 54 61
20008195 2009
24
General changes in hemostasis in gastric cancer. 54 61
19507648 2009
25
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation. 54 61
19174256 2009
26
Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. 54 61
18760517 2008
27
Familial chronic myeloproliferative disorders: the state of the art. 54 61
18484677 2008
28
Incidence and clinical significance of left ventricular thrombus in tako-tsubo cardiomyopathy assessed with echocardiography. 54 61
18334499 2008
29
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. 54 61
18367486 2008
30
Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role? 54 61
18397204 2008
31
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. 54 61
18160670 2008
32
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. 54 61
18616871 2008
33
Clinical implications of JAK2 mutations in myeloproliferative disorders. 54 61
18575049 2008
34
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. 54 61
17688946 2008
35
Thrombopoietin levels increased in patients with severe acute respiratory syndrome. 54 61
18314161 2008
36
Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. 54 61
18041648 2007
37
JAK2 mutations and clinical practice in myeloproliferative neoplasms. 54 61
18032973 2007
38
Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. 54 61
17920755 2007
39
Neonatal thrombocytosis following G-CSF treatment. 54 61
17917868 2007
40
Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle? 54 61
18220909 2007
41
Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. 54 61
17171694 2007
42
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation. 54 61
17285276 2007
43
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. 54 61
16820206 2007
44
[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]. 54 61
18094555 2007
45
[Blood cytokine levels as a clinical laboratory test]. 54 61
17441472 2007
46
JAK-2 mutations and their relevance to myeloproliferative disease. 54 61
17133099 2007
47
Characteristic changes in platelet-large cell ratio, lactate dehydrogenase and C-reactive protein in thrombocytosis-related diseases. 54 61
17622783 2007
48
Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. 54 61
17164950 2006
49
Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders. 54 61
17249502 2006
50
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. 54 61
16912229 2006
Sources

Variations for Thrombocytosis

About this section
Sources

Expression for Thrombocytosis

About this section
Search GEO for disease gene expression data for Thrombocytosis.
Sources

Pathways for Thrombocytosis

About this section

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.04 PPBP LIF KITLG JAK2 IL6 IL3
2
ERK Signaling 63
Show member pathways
 13.8 THPO PPBP LIF KITLG JAK2 IL6
3
PEDF Induced Signaling 63
Show member pathways
 13.65 THPO PPBP MPL LIF JAK2 IL6
4
TGF-Beta Pathway 63
Show member pathways
 13.51 THPO PPBP MPL KITLG JAK2 IL6
5
Akt Signaling 63
Show member pathways
 13.41 THPO PPBP LIF KITLG JAK2 IL6
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.35 LIF KITLG JAK2 IL6 IL3 IL1B
7
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.25 THPO SERPINC1 SELP PPBP MPL JAK2
8
PAK Pathway 63
Show member pathways
 13.21 THPO PPBP LIF KITLG JAK2 IL6
9
p70S6K Signaling 63
Show member pathways
 13.05 THPO PPBP KITLG JAK2 IL6 IL3
10
PI3K-Akt signaling pathway 36
Show member pathways
 12.99 KITLG JAK2 IL6 IL3 EPO CSF3
11
Pathways in cancer 36
12.85 KITLG JAK2 IL6 IL3 F2 EPO
12
NF-KappaB Family Pathway 63
Show member pathways
 12.7 THPO PPBP KITLG IL6 IL3 IL1B
13
NF-kappaB Signaling 4
12.57 MPL KITLG JAK2 IL3 IL1B
14
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.39 THPO PPBP KITLG IL6 IL3
15
IL-17 Family Signaling Pathways 64
Show member pathways
 12.34 JAK2 IL6 IL1B CSF3 CSF2
16
Folate Metabolism 1
Show member pathways
 12.32 IL6 IL1B F2 CRP
17
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.26 THPO PPBP KITLG IL6 IL3 IL1B
18
Bacterial infections in CF airways 22
Show member pathways
 12.19 JAK2 IL6 IL1B IL11
19
Kit receptor signaling pathway 1
Show member pathways
 12.18 KITLG JAK2 IL3 EPO
20
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 12.17 SERPINC1 F3 F2 CD177
21
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.11 THPO LIF KITLG IL6 IL3 IL11
22
Microglia Activation During Neuroinflammation: Overview 64
Show member pathways
 12.05 IL6 IL1B F2 CSF2
23
Interleukin-4 and 13 signaling 65
12 LIF JAK2 IL6 IL1B
24
TNF signaling pathway 36
11.98 LIF IL6 IL1B CSF2
25
Visual Cycle in Retinal Rods 63
11.92 THPO MPL JAK2 CRP
26
AGE-RAGE signaling pathway in diabetic complications 36
11.92 JAK2 IL6 IL1B F3
27
Jak-Stat Signaling Pathway (sino) 66
11.91 JAK2 IL6 IL3 EPO
28
Rheumatoid arthritis 36
11.89 IL6 IL1B IL11 CSF2
29
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.88 JAK2 IL6 CSF3 CSF2
30
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.87 THPO MPL KITLG IL6 IL3 IL11
31
IL-6 signaling pathway 1
Show member pathways
 11.81 JAK2 IL6 CRP
32
Salmonella infection (KEGG) 36
11.77 IL6 IL1B CSF2
33
Dendritic Cells Developmental Lineage Pathway 64
11.74 IL6 IL1B CSF2
34
G-protein signaling_RhoA regulation pathway 22
11.74 THPO PPBP KITLG IL6 IL3
35
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.71 IL6 IL1B CSF2
36
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 11.69 THPO MPL LIF JAK2 IL6 IL3
37
Lung fibrosis 1
11.67 IL6 IL1B CSF3 CSF2
38
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.66 IL6 IL1B CSF2
39
Interleukin-6 family signaling 65
Show member pathways
 11.62 LIF JAK2 IL6 IL11
40
Hematopoietic cell lineage 36
11.6 THPO KITLG IL6 IL3 IL1B IL11
41
Interleukin-10 signaling 65
11.57 LIF IL6 IL1B CSF3 CSF2
42
Malaria 36
11.55 SELP IL6 IL1B CSF3
43
Differentiation Pathway 1
11.54 KITLG IL6 IL3 IL11 EPO
44
Hematopoietic Stem Cell Differentiation 1
11.48 KITLG IL6 IL3 IL1B EPO CSF3
45
Cytokines and Inflammatory Response 1
11.26 IL6 IL3 IL1B IL11 CSF3 CSF2
46
G-protein signaling_Rap2B regulation pathway 22
10.97 THPO PPBP LIF KITLG IL6 IL3
Sources

GO Terms for Thrombocytosis

About this section

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 THPO SERPINC1 PPBP LIF KITLG IL6
2 extracellular space GO:0005615 9.53 THPO SERPINC1 SELP PPBP LIF KITLG

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 LIF IL6 IL1B CSF2 CRP
2 inflammatory response GO:0006954 9.99 SELP PPBP IL6 IL1B CRP
3 immune response GO:0006955 9.95 PPBP LIF IL6 IL3 IL1B CSF3
4 leukocyte migration GO:0050900 9.91 SELP IL1B F2 CD177
5 MAPK cascade GO:0000165 9.89 KITLG JAK2 IL3 IL1B CSF2
6 positive regulation of protein kinase B signaling GO:0051897 9.88 THPO KITLG F3 CSF3
7 response to lipopolysaccharide GO:0032496 9.88 SELP JAK2 IL1B EPO
8 blood coagulation GO:0007596 9.85 SERPINC1 JAK2 F3 F2 CD177
9 positive regulation of MAPK cascade GO:0043410 9.84 THPO LIF IL6 IL11
10 cellular response to lipopolysaccharide GO:0071222 9.83 PPBP IL6 IL1B CSF3 CSF2
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.81 JAK2 IL6 IL1B CSF3
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 LIF IL6 IL11 CSF3
13 hemostasis GO:0007599 9.77 SERPINC1 F3 F2
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 LIF JAK2 IL6 IL3 EPO CSF2
15 embryo implantation GO:0007566 9.72 LIF IL1B EPO
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 SELP JAK2 F2 EPO CSF3
17 positive regulation of Ras protein signal transduction GO:0046579 9.7 KITLG JAK2 EPO
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 LIF KITLG JAK2 IL6 IL3 IL11
19 acute-phase response GO:0006953 9.67 IL6 F2 EPO CRP
20 cytokine-mediated signaling pathway GO:0019221 9.65 MPL LIF JAK2 IL6 IL3 IL1B
21 positive regulation of neuroinflammatory response GO:0150078 9.64 IL6 IL1B
22 regulation of blood coagulation GO:0030193 9.64 SERPINC1 F2
23 negative regulation of hormone secretion GO:0046888 9.63 LIF IL11
24 negative regulation of lipid storage GO:0010888 9.63 IL6 CRP
25 tyrosine phosphorylation of STAT protein GO:0007260 9.62 LIF JAK2
26 ectopic germ cell programmed cell death GO:0035234 9.61 KITLG IL1B
27 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.57 THPO KITLG
28 thrombopoietin-mediated signaling pathway GO:0038163 9.56 THPO MPL
29 positive regulation of cell proliferation GO:0008284 9.4 THPO LIF KITLG JAK2 IL6 IL3

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.65 THPO PPBP LIF KITLG IL6 IL3
2 cytokine activity GO:0005125 9.36 THPO PPBP LIF KITLG IL6 IL3
Sources

Sources for Thrombocytosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....